Actemra

Actemra® (tocilizumab) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Polyarticular Juvenile Idiopathic Arthritis (PJIA) ​Actemra® (tocilizumab) is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Systemic Juvenile Idiopathic Arthritis (SJIA) Actemra® (tocilizumab) is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older.

ACTEMRA RA treatment is available through 2 methods. These options give you the ability to take your medicine in a way that works for you. Both options are proven to help reduce the symptoms of RA. ACTEMRA is available to treat rheumatoid arthritis (RA) as: Subcutaneous (SC) injection: an injection under the skin that you give yourself at home, or that a caregiver may give you Intravenous (IV) infusion: liquid medicine given into a vein at a doctor’s office or an infusion clinic